Literature DB >> 16096372

The role of CREB as a proto-oncogene in hematopoiesis.

Kentaro Kinjo1, Salemiz Sandoval, Kathleen M Sakamoto, Deepa B Shankar.   

Abstract

Cyclic-AMP response element binding protein (CREB) is a transcription factor that functions in glucose homeostasis, growth-factor- dependent cell survival, proliferation and memory. Signaling by hematopoietic growth factors, such as GM-CSF, results in activation of CREB and upregulation of CREB target genes. Data from our laboratory shows that a majority of patients with acute lymphoid and myeloid leukemia overexpress CREB in the bone marrow. CREB overexpression is associated with poor initial outcome of clinical disease in AML patients. To study its role in hematopoiesis, we overexpressed CREB in leukemia cell lines and in mice. CREB overexpression resulted in increased survival and proliferation of myeloid cells and blast-transformation of bone marrow progenitor cells from transgenic mice expressing CREB in the myeloid lineage. CREB transgenic mice also develop myeloproliferative disease after one year. Thus, CREB acts as a proto-oncogene to regulate hematopoiesis and contributes to the leukemia phenotype. Our results suggest that CREB-dependent pathways may serve as targets for directed therapies in leukemia in the future.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16096372     DOI: 10.4161/cc.4.9.1991

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  21 in total

1.  Targeting CREB for cancer therapy: friend or foe.

Authors:  Xiangshu Xiao; Bingbing X Li; Bryan Mitton; Alan Ikeda; Kathleen M Sakamoto
Journal:  Curr Cancer Drug Targets       Date:  2010-06       Impact factor: 3.428

2.  Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth.

Authors:  Chen Chen; Xin Wei; Xiaoquan Rao; Jun Wu; Shenglan Yang; Fuqiong Chen; Ding Ma; Jianfeng Zhou; Ryan T Dackor; Darryl C Zeldin; Dao Wen Wang
Journal:  J Pharmacol Exp Ther       Date:  2010-10-28       Impact factor: 4.030

3.  Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma.

Authors:  James R Cerhan; Stephen M Ansell; Zachary S Fredericksen; Neil E Kay; Mark Liebow; Timothy G Call; Ahmet Dogan; Julie M Cunningham; Alice H Wang; Wen Liu-Mares; William R Macon; Diane Jelinek; Thomas E Witzig; Thomas M Habermann; Susan L Slager
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

4.  Progesterone inhibition of voltage-gated calcium channels is a potential neuroprotective mechanism against excitotoxicity.

Authors:  Jessie I Luoma; Brooke G Kelley; Paul G Mermelstein
Journal:  Steroids       Date:  2011-03-01       Impact factor: 2.668

5.  p-CREB expression in human meningiomas: correlation with angiogenesis and recurrence risk.

Authors:  Valeria Barresi; Giovanni Branca; Maria Caffo; Giovanni Tuccari
Journal:  J Neurooncol       Date:  2015-01-07       Impact factor: 4.130

6.  CREB5 promotes tumor cell invasion and correlates with poor prognosis in epithelial ovarian cancer.

Authors:  Shanyang He; Yalan Deng; Yanbin Liao; Xiaojin Li; Jun Liu; Shuzhong Yao
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

Review 7.  CREB and leukemogenesis.

Authors:  Er-Chieh Cho; Bryan Mitton; Kathleen M Sakamoto
Journal:  Crit Rev Oncog       Date:  2011

Review 8.  Significance of oncogenes and tumor suppressor genes in AML prognosis.

Authors:  Maria Kavianpour; Ahmad Ahmadzadeh; Saeid Shahrabi; Najmaldin Saki
Journal:  Tumour Biol       Date:  2016-05-14

9.  The transcription factor ST18 regulates proapoptotic and proinflammatory gene expression in fibroblasts.

Authors:  Julia Yang; Michelle F Siqueira; Yugal Behl; Mani Alikhani; Dana T Graves
Journal:  FASEB J       Date:  2008-08-01       Impact factor: 5.191

10.  Inhibition of CREB function in mouse epidermis reduces papilloma formation.

Authors:  Julian Rozenberg; Vikas Rishi; Andras Orosz; Jaideep Moitra; Adam Glick; Charles Vinson
Journal:  Mol Cancer Res       Date:  2009-05-12       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.